256 Newsroom — Uganda's Digital News Infrastructure
World

Could one daily pill narrow the diabetes treatment gap in the Global South?

Share
Could one daily pill narrow the diabetes treatment gap in the Global South?
Image · Al Jazeera

What the report says

Al Jazeera reports that diabetes treatment is shifting from weekly injections to once-daily oral GLP-1 pills, a change that could improve access in the Global South, where cold-chain storage, cost and insurance coverage can be major barriers. The piece says the newer tablets may be especially important for countries with high diabetes burdens and limited healthcare infrastructure, including Pakistan and several Middle Eastern and Pacific states.

The article highlights that GLP-1 medicines such as semaglutide and tirzepatide have already transformed care for type 2 diabetes and obesity, but injectable versions remain expensive. It notes that locally manufactured oral semaglutide could cost far less than branded injections and would be easier to distribute in rural areas because it does not require refrigeration. Doctors quoted in the article said these drugs can help with blood sugar control and weight loss, and may also improve related conditions such as heart, kidney and liver disease.

Al Jazeera also traces the science behind the drugs, describing how researchers identified GLP-1 as a gut hormone involved in insulin release and appetite regulation. The article says that discovery helped lead to semaglutide and later tirzepatide, with another drug, retatrutide, still in trials. It adds broader context from the World Health Organization and industry forecasts, underscoring why the market is expanding as obesity and diabetes remain major global health challenges.

Read the full report at Al Jazeera →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

Related reporting